CNBX Pharmaceuticals Inc. (CNBX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 08-31. Amounts in USD.

Revenue Quarterly

0 150K 300K 450K Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q3 '22: 0 Q4 '22: 30K Q1 '23: 0 Q2 '23: 0 Q3 '23: 310.2K Q4 '23: 100K Q1 '24: 89.4K Q2 '24: 40.6K Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q3 '26: 0 Q3 '21 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Gross Profit Quarterly

0 20K 40K 60K Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q2 '16: 12.5K Q3 '16: 50K Q4 '16: 50K Q1 '17: 0 Q2 '17: 1.2K Q3 '17: 1.6K Q4 '17: 2.9K Q1 '18: 1.8K Q2 '18: 1.9K Q1 '19: 3.3K Q2 '23: 0 Q2 '24: 34.4K Q2 '25: 0 Q3 '25: 0 Q2 '26: 0 Q3 '26: 0 Q2 '15 Q2 '16 Q1 '17 Q4 '17 Q1 '19 Q2 '25 Q3 '26

Operating Income Quarterly

-1.2M -800K -400K 0 400K 800K 1.2M Q4 '21: -596.3K Q1 '22: -1.1M Q2 '22: -730.3K Q3 '22: -635K Q4 '22: -478.4K Q1 '23: -346.8K Q2 '23: -250K Q3 '23: -173.1K Q4 '23: -161.5K Q1 '24: -171.9K Q2 '24: -206.4K Q3 '24: -152.3K Q4 '24: -52.5K Q1 '25: -36.8K Q2 '25: -64.7K Q3 '25: -40.4K Q4 '25: -129.7K Q1 '26: -64K Q2 '26: -73K Q3 '26: -162.8K Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income Quarterly

-2.7M -1.8M -900K 0 900K 1.8M 2.7M Q4 '21: -681.1K Q1 '22: -1.3M Q2 '22: -1.2M Q3 '22: -681.7K Q4 '22: -479.7K Q1 '23: -357.7K Q2 '23: -2.6M Q3 '23: -154.7K Q4 '23: -573.6K Q1 '24: -178.5K Q2 '24: -325.5K Q3 '24: -130.6K Q4 '24: -60.6K Q1 '25: -34.4K Q2 '25: -69.8K Q3 '25: -59.7K Q4 '25: -150.1K Q1 '26: -113.7K Q2 '26: -44.1K Q3 '26: -154.2K Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Cost of Revenue Quarterly

0 2.5K 5K 7.5K Q2 '15: 0 Q3 '15: 0 Q2 '16: 0 Q3 '16: 0 Q2 '17: 0 Q3 '17: 0 Q2 '18: 0 Q2 '23: 0 Q2 '24: 6.2K Q2 '25: 0 Q3 '25: 0 Q2 '26: 0 Q3 '26: 0 Q2 '15 Q2 '16 Q2 '17 Q2 '18 Q2 '24 Q3 '25 Q3 '26

Operating Cash Flow Quarterly

-750K -500K -250K 0 250K 500K 750K Q4 '21: -581.8K Q1 '22: -599.5K Q2 '22: -554.8K Q3 '22: -375.4K Q4 '22: -149.5K Q1 '23: -95.9K Q2 '23: -18.5K Q3 '23: -18.6K Q4 '23: 20.5K Q1 '24: -71.8K Q2 '24: -124.4K Q3 '24: 225 Q4 '24: -48.2K Q1 '25: -39.1K Q2 '25: -51.7K Q3 '25: -52K Q4 '25: -28.5K Q1 '26: -47.4K Q2 '26: -30.5K Q3 '26: -47.7K Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow Quarterly

-120K -80K -40K 0 40K 80K 120K Q1 '15: -113.3K Q2 '15: -55.2K Q3 '15: 13.7K Q1 '16: -35.7K Q2 '16: -26.2K Q3 '16: 11.1K Q1 '15 Q2 '15 Q3 '15 Q1 '16 Q2 '16 Q3 '16

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 500M 1B 1.5B Q2 '21: 135.2M Q3 '21: 1.1M Q1 '22: 131.1M Q2 '22: 1.2M Q3 '22: 1.2M Q1 '23: 1.3M Q2 '23: 2M Q3 '23: 9.3M Q1 '24: 27.8M Q2 '24: 31M Q3 '24: 31.1M Q1 '25: 31.1M Q2 '25: 32.1M Q3 '25: 42.6M Q1 '26: 732.9M Q2 '26: 931M Q3 '26: 1.3B Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q4 '20: -0.14 Q1 '21: -0.11 Q2 '21: -0.10 Q3 '21: -1.22 Q4 '21: -1.18 Q1 '22: -1.19 Q2 '22: -2.20 Q3 '23: -2.62 Q4 '23: -0.42 Q1 '24: -0.10 Q2 '24: 1.22 Q3 '24: 1.24 Q4 '24: -0.02 Q1 '25: -0.01 Q2 '25: -0.00 Q3 '25: -0.00 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q3 '26: 0.00 Q1 '21 Q4 '21 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.